R1 and ColIb-p9 Plasmids: Antisense RNA. Most plasmids require a plasmid-encoded protein, usually called Rep, to separate the strands of DNA at the origin of replication (oriV) to initiate DNA replication. Rep binds to specific DNA sequences in oriV which are unique to a plasmid type. The synthesis of Rep protein is controlled in order to limit
The first therapeutic nucleic acid, a DNA oligonucleotide, was approved for clinical use in 1998. Twenty years later, in 2018, the first therapeutic RNA-based oligonucleotide was United States Food and Drug Administration (FDA) approved. This promises to be a rapidly expanding market, as many emerging biopharmaceutical companies are developing RNA interference (RNAi)-based, and RNA-based
. 9rk8f0i0wq.pages.dev/1959rk8f0i0wq.pages.dev/3559rk8f0i0wq.pages.dev/4939rk8f0i0wq.pages.dev/2059rk8f0i0wq.pages.dev/4999rk8f0i0wq.pages.dev/1049rk8f0i0wq.pages.dev/3109rk8f0i0wq.pages.dev/91
what is antisense dna
